Rheumatology

Filter

Twenty-five years of etanercept

4 Mins

December 2025

Rheumatologist Rieke Alten discusses how treat-to-target care and TNF inhibition with etanercept reshape RA outcomes, with safety…

The International Osteoporosis Foundation Continues Campaign to Raise Awareness of Osteoporosis

To mark this year’s World Osteoporosis Day (WOD) on the 20th October 2017, the European Medical Journal spoke to the International Osteoporosis…

Spasmodic Dysphonia: What About It?

Spasmodic dysphonia (SD): what about it? That is the million-dollar question.

Biosimilars and Switching: What is your Perspective?

The licensing of biosimilars heralds the start of a new era for physicians treating immune and inflammatory diseases.

Switching Patients from Originator to Biosimilar Medications in Rheumatoid Arthritis: Limiting The ‘Nocebo’ Effect

Biosimilars have been available in Europe since 2006, and biosimilars of monoclonal antibodies since 2013, and are now a widespread clinical reality.

The Patient’s Perspective on Psoriatic Arthritis: What more can Rheumatologists do to Optimise Disease Management?

The symposium at the EULAR 2017 congress aimed to provide insights into the burden of psoriatic arthritis on patients’ daily lives, including the…

Editor’s Pick: Why do Diseases Start One Sided? Clues From HLA-B27 Acute Anterior Uveitis

Uveitis is an inflammatory disease with significant disease burden, as it causes ≤10% of legal blindness in the USA.

Osmolytes as Mediators of the Muscle Tissue’s Responses to Inflammation: Emerging Regulators of Myositis with Therapeutic Potential

In this review, the role of the organic osmolytes taurine, betaine, myo-inositol, and sorbitol in skeletal muscles in general, and in myositis in…

Advances in Epigenetics and Integration of Omics in Lupus

Systemic lupus erythematosus is a chronic, multi-organ disease that predominantly affects young women of childbearing age.

Loading posts...

« Previous 1 … 14 15 16 17 18 … 22 Next »